Type 2 diabetes clinical trial success rates U.S. 2006-2015, by phase and indication

Published by
Matej Mikulic,
Apr 18, 2019
This statistic depicts the percentage of U.S. type 2 diabetes clinical trials for novel drugs that were successful in the period from 2006 to 2015, by phase and indication. Among diabetes NME/biologics just 4.8 percent were successful from phase I to approval.

Clinical trial success rates of novel type 2 diabetes drugs between 2006 and 2015, by phase and indication

© Statista 2023
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

2019

Region

United States

Survey time period

2006 to 2015

Supplementary notes

NDA/BLA = new drug application/biologic license application
NME = new molecular entity

Citation formats
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Starter Account
The ideal entry-level account for individual users
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$149 USD / Month *
Professional Account
Full access

Business Solutions including all features.

* Prices do not include sales tax.

Other statistics that may interest you

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Statistics on

About the industry

10

About the region

10

Selected statistics

6

Other regions

10

Related statistics

10

Further related statistics

10

Further Content: You might find this interesting as well

Statistics

Topics

Biotech drugsGlobal pharmaceutical industryCancer in the U.S.AmgenCoronavirus (COVID-19) vaccines and treatments
Statista Accounts: Access All Statistics. Starting from $1,788 USD / Year
Learn more about how Statista can support your business.
Menu